

UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENT	OR	. A	TTORNEY DOCKET NO.
09/149,721	09/08/9	8 MUMPER		R	237/023
	HM22/1026			EXAMINER	
LYON AND LYON LLP				OWENS JR.H	
SUITE 4700				ART UNIT	PAPER NUMBER
633 WEST FIFTH STREET LOS ANGELES CA 90071-2066				1623	12
			DAT	E MAILED:	10/26/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Application No. 09/149,721

Applicant(s)

Mumper et al.

Office Action Summary Examiner

Howard Owens

Group Art Unit 1623



Responsive to communication(s) filed on Jan 27, 2000	·		
This action is FINAL.			
Since this application is in condition for allowance except for in accordance with the practice under <i>Ex parte Quayle</i> , 193	35 C.D. 11; 453 O.G. 213.		
shortened statutory period for response to this action is set to longer, from the mailing date of this communication. Failure oplication to become abandoned. (35 U.S.C. § 133). Extens 7 CFR 1.136(a).	to respond within the period for response will cause the		
isposition of Claims			
	is/are pending in the application.		
Of the above, claim(s)	is/are withdrawn from consideration.		
Claim(s)			
Claim(s)			
☐ Claims	are subject to restriction or election requirement.		
pplication Papers See the attached Notice of Draftsperson's Patent Drawin The drawing(s) filed on is/are objected. The proposed drawing correction, filed on is/are objected to by the Examiner. The specification is objected to by the Examiner. The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. § 119 Acknowledgement is made of a claim for foreign priority in All Some* None of the CERTIFIED copies received.	ted to by the Examiner. is approved disapproved. y under 35 U.S.C. § 119(a)-(d). of the priority documents have been		
☐ received in Application No. (Series Code/Serial No. ☐ received in this national stage application from the			
*Certified copies not received:	rity under 35 U.S.C. § 119(e).		
Attachment(s) Notice of References Cited, PTO-892 Information Disclosure Statement(s), PTO-1449, Paper Interview Summary, PTO-413 Notice of Draftsperson's Patent Drawing Review, PTO-152	No(s)		
SEE OFFICE ACTION ON	N THE FOLLOWING PAGES		

2

Serial No. 09/149,721

Art Unit 1623

Response to Arguments

5 The following is in response to the amendment filed 1-27-00:

An action on the merits of claims 1 and 7-9 is contained herein below.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claims 2-6 have been canceled by applicant.

Withdrawal of finality

The finality of the rejection of the last Office action is withdrawn in view of the citation of new art.

Objection to claims

Claims 7-9 are objected to for the absence of a period.

Sequence Listing

This application contains sequence disclosures (pages 41 and 51) that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g).

25

10

15

20

Art Unit 1623

35 U.S.C. 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. § 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1 and 7-9 are rejected under 35 U.S.C. § 102(b) as being anticipated by Boullanger et al., *Carbohydrate Research*, vol. 278, 1995, pp. 91-101 or Miyajima et al., EP 457910 A1.

The instant claims are drawn to a glycosylamine compound wherein R_1 is O-alkyl. Boullanger et al. anticipates this claim as it teaches an alkylated glycosylamine analogous to that set forth in the claims cited supra (p. 95, scheme 2, step ii).

In claim 1, wherein R_5 is O-C-O-alkyl and R_1 is alkyl, Myajima anticipates the claim as it teaches an alkylated glucosamine methylglycoside (p. 11, lines 15-50).

5

10

15

Serial No. 09/149,721

Art Unit 1623

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Howard Owens whose telephone number is (703) 306-4538. The examiner can normally be reached on Mon.-Fri. from 8:30 a.m. to 5 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the Primary Examiner signing this action, Gary Geist can be reached on (703) 308-1701. The fax phone number for this Group is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-1235.

Howard Owens

Group 1623

15

5

10

GARY GEIST SUPERVISORY PATENT EXAMINER TECH CENTER 1600